Antoine F Carpentier

Summary

Country: France

Publications

  1. ncbi Recent advances in immunotherapy for human glioma
    Antoine F Carpentier
    Department of Neurology, Mazarin, Salpetriere Hospital, Paris, France
    Curr Opin Oncol 18:631-6. 2006
  2. ncbi Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
    Alexandre Carpentier
    Department of Neurosurgery, Hopital Lariboisiere, Paris, France
    Neuro Oncol 12:401-8. 2010
  3. ncbi Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
    Claire Banissi
    Laboratoire de Recherches Biochirurgicales, Universite Paris Descartes, Paris, France
    Cancer Immunol Immunother 58:1627-34. 2009
  4. ncbi Expression of TLR9 within human glioblastoma
    Yuxia Meng
    INSERM U711, Biologie des Interactions Neurones and Glie, Paris, France
    J Neurooncol 88:19-25. 2008
  5. ncbi Dynamic history of low-grade gliomas before and after temozolomide treatment
    Damien Ricard
    Institut National de la Sante et de la Recherche Medicale, U711, Paris, France
    Ann Neurol 61:484-90. 2007
  6. ncbi Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
    Alexandre Carpentier
    Department of Neurology, , Paris, France
    Neuro Oncol 8:60-6. 2006
  7. ncbi Adjuvant properties of Cytosine-phosphate-guanosine oligodeoxynucleotide in combination with various polycations in an ovalbumin-vaccine model
    Sylvie Maubant
    Laboratoire de Recherches Biochirurgicales, Hopital Europeen Georges Pompidou, Universite Paris Descartes, Paris, France
    Nucleic Acid Ther 21:231-40. 2011
  8. ncbi Primary brain tumours in adults
    Anthony Behin
    , , 75013, Paris, France
    Lancet 361:323-31. 2003
  9. ncbi Successful combination of local CpG-ODN and radiotherapy in malignant glioma
    Yuxia Meng
    , UMR-495, , Paris, France
    Int J Cancer 116:992-7. 2005
  10. ncbi CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease
    Gregor Auf
    , , 75013, Paris, France
    Neurosci Lett 327:189-92. 2002

Collaborators

Detail Information

Publications20

  1. ncbi Recent advances in immunotherapy for human glioma
    Antoine F Carpentier
    Department of Neurology, Mazarin, Salpetriere Hospital, Paris, France
    Curr Opin Oncol 18:631-6. 2006
    ..The present review focuses on recent progress in tumour immunology and immunotherapeutic trials in malignant gliomas...
  2. ncbi Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
    Alexandre Carpentier
    Department of Neurosurgery, Hopital Lariboisiere, Paris, France
    Neuro Oncol 12:401-8. 2010
    ..The molecular or clinical characteristics of a subgroup of patients that could potentially benefit from such an approach remain to be defined...
  3. ncbi Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
    Claire Banissi
    Laboratoire de Recherches Biochirurgicales, Universite Paris Descartes, Paris, France
    Cancer Immunol Immunother 58:1627-34. 2009
    ..We therefore studied the impact of various TMZ regimens on Treg cell population in a TMZ-resistant rat model of glioma...
  4. ncbi Expression of TLR9 within human glioblastoma
    Yuxia Meng
    INSERM U711, Biologie des Interactions Neurones and Glie, Paris, France
    J Neurooncol 88:19-25. 2008
    ..Immunocytochemistry studies showed TLR9 expression in some macrophages/microglial cells. The expression of TLR9 within human GBM strengthens the rationale for the utilization of CpG-ODN in this disease...
  5. ncbi Dynamic history of low-grade gliomas before and after temozolomide treatment
    Damien Ricard
    Institut National de la Sante et de la Recherche Medicale, U711, Paris, France
    Ann Neurol 61:484-90. 2007
    ..To evaluate the natural progression and the impact of temozolomide in low-grade gliomas and to correlate these changes with the profile of genetic alterations...
  6. ncbi Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
    Alexandre Carpentier
    Department of Neurology, , Paris, France
    Neuro Oncol 8:60-6. 2006
    ..2 months. In conclusion, CpG-28 was well tolerated at doses up to 20 mg per injection in patients with recurrent glioblastoma. Main side effects were limited to transient worsening of neurological condition and fever...
  7. ncbi Adjuvant properties of Cytosine-phosphate-guanosine oligodeoxynucleotide in combination with various polycations in an ovalbumin-vaccine model
    Sylvie Maubant
    Laboratoire de Recherches Biochirurgicales, Hopital Europeen Georges Pompidou, Universite Paris Descartes, Paris, France
    Nucleic Acid Ther 21:231-40. 2011
    ..Interestingly, CpG ODN-poly-arginine, which was the most efficient, compared favorably to the complete Freund's adjuvant and aluminium salts and induced no local toxicity, making this combination a very attractive adjuvant for vaccines...
  8. ncbi Primary brain tumours in adults
    Anthony Behin
    , , 75013, Paris, France
    Lancet 361:323-31. 2003
    ....
  9. ncbi Successful combination of local CpG-ODN and radiotherapy in malignant glioma
    Yuxia Meng
    , UMR-495, , Paris, France
    Int J Cancer 116:992-7. 2005
    ..These results support an attractive strategy of sequential radiotherapy and immunotherapy by CpG-ODN and have potential implications for future clinical trials with CpG-ODN...
  10. ncbi CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease
    Gregor Auf
    , , 75013, Paris, France
    Neurosci Lett 327:189-92. 2002
    ..None of the animals developed neurological disabilities and histological studies of the nervous system were normal. CpG-ODN can therefore trigger neuroblastoma rejection without inducing neurological paraneoplastic disease...
  11. ncbi PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia
    Rose Ann Padua
    LBCH INSERM E0 03, U462 and U396, Institut Universitaire d Hematologie, Hopital Saint Louis, AP HP 75010, Paris, France
    Nat Med 9:1413-7. 2003
    ..When DNA vaccination and conventional ATRA therapy are combined, they induce protective immune responses against leukemia progression in mice and may provide a new approach to improve clinical outcome in human leukemia...
  12. ncbi CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma
    Antoine F Carpentier
    Fédération de Neurologie Mazarin, Hopital de la Salpetriere, 75013 Paris, France
    Front Biosci 8:e115-27. 2003
    ..In malignant gliomas, intra-tumoral injections of CpG-ODN represent a practical approach. Indeed, human gliomas display a locally invasive pattern of growth and rarely metastasize, making local treatment clinically relevant...
  13. ncbi Continuous growth of mean tumor diameter in a subset of grade II gliomas
    Emmanuel Mandonnet
    , and Service de Neurochirurgie, , Paris
    Ann Neurol 53:524-8. 2003
    ..These findings could be of interest to optimize patients management and follow-up...
  14. ncbi Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses
    Stephan Roux
    INSERM U805, Villejuif, France
    Cancer Immunol Immunother 57:1291-300. 2008
    ..We addressed whether tumor-associated antigens released after ECT could induce an efficient systemic immunity when associated with an appropriate immunoadjuvant...
  15. ncbi [New therapeutic approaches in glioblastomas]
    Antoine F Carpentier
    Service de Neurologie, Hopital de la Salpetriere, 57, Bd de l Hopital, 75013 Paris
    Bull Cancer 92:355-9. 2005
    ..This article reviews these emerging therapies currently under clinical trials in glioblastomas...
  16. ncbi Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection
    Nathalie Chaput
    , , Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
    J Immunol 172:2137-46. 2004
    ..CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines...
  17. ncbi Neuro-oncology: the growing role of chemotherapy in glioma
    Antoine F Carpentier
    Department of Neurology Mazarin, , France
    Lancet Neurol 4:4-5. 2005
  18. ncbi Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines
    Julien Taieb
    , , Institut Gustave Roussy, Villejuif, France
    J Immunol 176:2722-9. 2006
    ..Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of CD4+CD25+ regulatory T cells...
  19. ncbi [Cancer immunotherapy with CpG-ODN]
    Antoine F Carpentier
    Fédération de Neurologie Mazarin et Inserm U 495, Hopital de la Salpetriere, 47, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Med Sci (Paris) 21:73-7. 2005
    ..Preclinical models have shown impressive results and several clinical trials are on-going worldwide in melanoma, lymphoma, renal carcinoma, breast cancer and glioblastoma...